Pharmachronicles

Top Menu

  • Home
  • Our Blog
  • Contact Us

Main Menu

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
Sign in / Join

Login

Welcome! Login in to your account
Lost your password?

Lost Password

Back to login
  • Home
  • Our Blog
  • Contact Us

logo

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
  • Overcoming Vaccine Hesitancy: How Pharmacists Build Patient Confidence

  • Resurgence of COVID-19 in Hong Kong and Singapore: A New Wave Driven by Waning Immunity and Emerging Variants

  • How Pharmacists Support Chronic Disease Management in the Community

  • OTC Medications: Safe Use, Common Mistakes, and Pharmacist Guidance

  • Pharmacovigilance Explained: Why Reporting Adverse Drug Reactions Saves Lives

BLOGS
Home›BLOGS›Besponsa (inotuzumab ozogamicin) a new FDA approved drug

Besponsa (inotuzumab ozogamicin) a new FDA approved drug

By admin
September 14, 2017
1239
0
Share:

Besponsa (inotuzumab ozogamicin) is a CD22-directed antibody-drug conjugate (ADC).

Besponsa is specifically indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Besponsa is supplied as a solution for intravenous injection. The recommended dose schedule is as follows:

For the first cycle: the recommended total dose of Besponsa for all patients is 1.8 mg/m2 per cycle, administered as 3 divided doses on Day 1 (0.8 mg/m2), Day 8 (0.5 mg/m2), and Day 15 (0.5 mg/m2). Cycle 1 is 3 weeks in duration, but may be extended to 4 weeks if the patient achieves a complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), and/or to allow recovery from toxicity.

For subsequent cycles: In patients who achieve a CR or CRi, the recommended total dose of Besponsa is 1.5 mg/m2per cycle, administered as 3 divided doses on Day 1 (0.5 mg/m2), Day 8 (0.5 mg/m2), and Day 15 (0.5 mg/m2). Subsequent cycles are 4 weeks in duration. OR  In patients who do not achieve a CR or CRi, the recommended total dose of Besponsa is 1.8 mg/m2 per cycle given as 3 divided doses on Day 1 (0.8 mg/m2), Day 8 (0.5 mg/m2), and Day 15 (0.5 mg/m2). Subsequent cycles are 4 weeks in duration. Patients who do not achieve a CR or CRi within 3 cycles should discontinue treatment.

For patients proceeding to hematopoietic stem cell transplant (HSCT), the recommended duration of treatment with Besponsa is 2 cycles. A third cycle may be considered for those patients who do not achieve CR or CRi and minimal residual disease (MRD) negativity after 2 cycles.

For patients not proceeding to HSCT, additional cycles of treatment, up to a maximum of 6 cycles, may be administered.

Please see drug label for specific dose modifications based on toxicities.

Clinical Results

FDA Approvals

The FDA approval of Besponsa was based on a randomized trial of 326 patients with relapsed or refractory B-cell ALL who had received one or two prior treatments. Patients were randomized to receive treatment with Besponsa or an alternative chemotherapy regimen. The trial measured the percentage of patients with no evidence of disease and full recovery of blood counts after treatment (complete remission or CR). Of the 218 evaluated patients, 35.8 percent who received Besponsa experienced CR for a median 8.0 months; of the patients who received alternative chemotherapy, 17.4 percent experienced CR for a median 4.9 months.

Side Effects

Adverse effects associated with the use of Besponsa may include, but are not limited to, the following:

  • thrombocytopenia
  • neutropenia
  • infection
  • anemia
  • leukopenia
  • fatigue
  • hemorrhage
  • pyrexia
  • nausea
  • headache
  • febrile neutropenia
  • transaminases increased
  • abdominal pain
  • gamma-glutamyltransferase increased
  • hyperbilirubinemia

The Besponsa drug label includes a boxed warning that severe liver damage (hepatotoxicity), including blockage of veins in the liver (veno-occlusive disease [VOD] or sinusoidal obstruction syndrome), occurred in some patients who took Besponsa.

Mechanism of Action

Besponsa (inotuzumab ozogamicin) is a CD22-directed antibody-drug conjugate (ADC). Inotuzumab recognizes human CD22.  The small molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of inotuzumab ozogamicin is due to the binding of the ADC to CD22-expressing tumor cells, followed by internalization of the ADC-CD22 complex, and the intracellular release of N-acetyl-gamma-calicheamicin dimethylhydrazide via hydrolytic cleavage of the linker. Activation of N-acetyl-gamma-calicheamicin dimethylhydrazide induces double-strand DNA breaks, subsequently inducing cell cycle arrest and apoptotic cell death.

 

Tagsantibody-drug conjugate.B-cell precursor acute lymphoblastic leukemiahematopoietic stem cell transplant
Previous Article

Useful websites and online educational support.

Next Article

DUAL CONTROL OF PHARMACY EDUCATION IN INDIA

0
Shares
  • 0
  • +
  • 0
  • 0
  • 0
  • 0

admin

Related articles More from author

  • BLOGS

    Industry wary over government’s new pharma policy

    August 24, 2017
    By admin
  • BLOGS

    CAN AN STRESS TRIGGERS HEART ATTACK.

    September 25, 2017
    By admin
  • Phama news

    Saroj Group Of Hospitals restarts its complete operations – see major footfall in OPD consultation

    June 1, 2020
    By Pharmachronicles
  • Phama news

    A glimpse about Coronovirus (2019-nCoV)

    January 31, 2020
    By Ramoju kishore kumar
  • pharmacy credit system
    BLOGSPhama news

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI to Implement

    February 1, 2025
    By Pharmachronicles
  • Green Pharma
    BLOGSPhama news

    Green Pharma: Redefining Healthcare for a Healthier Planet

    January 27, 2025
    By Pharmachronicles

Leave a reply Cancel reply

You may interested

  • pharmacy credit system
    BLOGSPhama news

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI to Implement

  • Trials

    Progression of rare connective tissue tumor controlled by targeted therapy

  • BLOGS

    FDA approval brings first gene therapy to the United States

  • LATEST REVIEWS

  • TOP REVIEWS

  • Pharmacists are not eligible for certificate program of community health

    0
  • A New Class of Antimicrobials Has Just Been Found in Human Breast Milk Fresh super ...

    0

Timeline

  • May 20, 2025

    Overcoming Vaccine Hesitancy: How Pharmacists Build Patient Confidence

  • May 17, 2025

    Resurgence of COVID-19 in Hong Kong and Singapore: A New Wave Driven by Waning Immunity and Emerging Variants

  • May 9, 2025

    How Pharmacists Support Chronic Disease Management in the Community

  • May 9, 2025

    OTC Medications: Safe Use, Common Mistakes, and Pharmacist Guidance

  • May 7, 2025

    Pharmacovigilance Explained: Why Reporting Adverse Drug Reactions Saves Lives

Latest Comments

  • Pharmachronicles
    on
    February 27, 2025
    Thank you sir

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI ...

  • G Krishna moorthy
    on
    February 1, 2025
    Good 👍 efforts Congratulations Continue your valuable professional services

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI ...

  • Aarati sonawane
    on
    January 31, 2025
    Use in toppical application

    Role of Artificial Intelligence in 3D Printing Personalized Medication

  • Sowmya V
    on
    December 13, 2019
    Nice keep it up

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

Find us on Facebook

Follow Us on Instagram

logo

Dui viverra Faucibus aliquet quis phasellus accumsan. Donec et facilisis sociosqu sed tortor elit eu aliquid turpis ridiculus.

Fly, shall, have greater fifth spirit midst under from stars thing is, had creepeth multiply kind. Man may they’re meat years have third bring replenish air two light deep fill.

About us

  • Dr.N.Sriram, Founder CEO, Pharmachronicles, HITS college of Pharmacy, Ghatkesar, Hyderabad, India
  • 9704361947
  • pharmachronicles@gmail.com
  • Recent

  • Popular

  • Comments

  • Overcoming Vaccine Hesitancy: How Pharmacists Build Patient Confidence

    By Pharmachronicles
    May 20, 2025
  • Resurgence of COVID-19 in Hong Kong and Singapore: A New Wave Driven by Waning Immunity ...

    By Pharmachronicles
    May 17, 2025
  • How Pharmacists Support Chronic Disease Management in the Community

    By Pharmachronicles
    May 9, 2025
  • OTC Medications: Safe Use, Common Mistakes, and Pharmacist Guidance

    By Pharmachronicles
    May 9, 2025
  • pharmacy credit system

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for ...

    By Pharmachronicles
    February 1, 2025
  • Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    By Sundari srinidhi
    December 12, 2019
  • Ai in 3D printing

    Role of Artificial Intelligence in 3D Printing Personalized Medication

    By Pharmachronicles
    January 29, 2025
  • FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    By admin
    July 16, 2015
  • Pharmachronicles
    on
    February 27, 2025

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI ...

    Thank you sir
  • G Krishna moorthy
    on
    February 1, 2025

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI ...

    Good 👍 efforts Congratulations ...
  • Aarati sonawane
    on
    January 31, 2025

    Role of Artificial Intelligence in 3D Printing Personalized Medication

    Use in toppical application
  • Sowmya V
    on
    December 13, 2019

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    Nice keep it up

Photostream

    Follow us

    • Contact
    • STUDENTS ZONE
    • About Us
    © Copyright Pharmachronicles. All rights reserved.